Abstract
Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Current Vascular Pharmacology
Title: Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.
Volume: 5 Issue: 2
Author(s): Massimo Franchini and Giuseppe Lippi
Affiliation:
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Abstract: Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Export Options
About this article
Cite this article as:
Franchini Massimo and Lippi Giuseppe, Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents., Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368325
DOI https://dx.doi.org/10.2174/157016107780368325 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano-Precipitation: Preparation and Application in the Field of Pharmacy
Current Pharmaceutical Design Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology
Current Pharmaceutical Design Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Texture-Based Classification of Periventricular Leukomalacia in Preterm Ultrasound Images
Current Medical Imaging Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Clinical and Forensic Signs Related to Opioids Abuse
Current Drug Abuse Reviews Systemic Delivery of siRNA: Challenging but Promising
Recent Patents on Drug Delivery & Formulation Sepsis and Solid Organ Transplantation
Current Drug Targets Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Effectiveness and Safety of Digoxin on Chronic Heart Failure
Current Pharmaceutical Analysis The Use of Sensory Nerve Stimulation and Compression Bandaging to Improve Sensory Nerve Function and Healing of Chronic Venous Leg Ulcers
Current Aging Science Preparation and Application of Mucoadhesive Nanoparticles Containing Enoxaparin in a Wound Healing Animal Model
Current Nanoscience How Much Iron is Needed for Breastfeeding Infants?
Current Pediatric Reviews Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Optimisation of Synthetic Vector Systems for Cancer Gene Therapy – The Role of the Excess of Cationic Dendrimer Under Physiological Conditions
Current Topics in Medicinal Chemistry Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews